| Prev Close | 125.93 |
| Open | 125.44 |
| Day Low/High | 125.44 / 129.49 |
| 52 Wk Low/High | 92.56 / 140.77 |
| Volume | 1.30M |
| Avg Volume | 1.65M |
| Exchange | NASDAQ |
| Shares Outstanding | 223.47M |
| Market Cap | 28.14B |
| EPS | 0.30 |
| P/E Ratio | 359.80 |
| Div & Yield | N.A. (N.A) |
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company has submitted marketing applications to the U.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 35th Annual J.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced today that it has filed with the Securities and Exchange Commission its Form 10-Q for the third quarter ended September 30, 2016.
Even among the losers, buys are scarce.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
The S&P 500 may be ending 2016 with double-digit gains, but almost a third of the index's individual stocks are actually down this year. Here's how to avoid the laggards.
Start 2017 on the right foot by selling your holdings in these five stocks.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Alexion Pharmaceuticals, Inc.
Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors in Alexion Pharmaceuticals, Inc.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
The biotech company has been taking a beating lately.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today reported results from the PROTECT Study, a Phase 2/3 registration trial of eculizumab (Soliris ®) for the prevention of delayed graft function (DGF) after kidney...
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alexion Pharmaceuticals, Inc.
Biogen promoted its current Chief Commercial Officer Michel Vounatsos to become the biotech company's next CEO.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Alexion Pharmaceuticals, Inc.
There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
The Dow posts a record close with the S&P 500 lower, while tech stocks dragged on the Nasdaq as Wall Street looks to a Fed decision on interest rates Tuesday.
The Dow rises but pares gains as Wall Street looks to a Fed decision on interest rates later in the week.
For health care investors, CEO vacancies at two of the six big-cap biotech companies aren't helping sentiment heading into 2017.
Here's a technical look on how to trade some of the most active stocks on the market this week.
Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Alexion Pharmaceuticals, Inc.
Stocks are mixed Monday as oil prices surge after non-OPEC countries agree to cut production and markets anticipate Fed moves.
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
Alexion Pharmaceuticals fired its CEO and chief financial officer Monday amidst an internal probe into allegations of improper sales practices tied to its top-selling drug Soliris.
The Board of Directors of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that it has named David Brennan as Interim Chief Executive Officer, effective immediately.
